



Curriculum vitae

Informazioni personali

Nome e cognome **Dario Carlo Angelo Baratti**

Indirizzo Fondazione IRCCS Istituto Nazionale dei Tumori
Via Venezian n.1, 20133 Milano

Telefono

Fax

E-mail dario.baratti@istitutotumori.mi.it

PEC

Nazionalità Italiana

Data di nascita 15.03.1964

Note biografiche

Il Dr. Dario Baratti ha svolto gran parte della sua vita professionale presso l'Istituto Nazionale dei Tumori di Milano. Entrato in Istituto come specializzando nel 1994, ha sviluppato le proprie competenze chirurgiche, scientifiche ed organizzative nel campo delle neoplasie addominali avanzate, fino a diventare un opinion leader di livello internazionale nel trattamento delle neoplasie peritoneali primitive e metastatiche mediante chirurgia citoriduttiva e HIPEC. Come tale, è membro dell'Advisory Board della Direzione Scientifica dell'Istituto Nazionale dei Tumori di Milano ed ha un publication track record di 133 paper indexati, per un H-index di 43 (Scopus). Inoltre è stato membro invitato della faculty agli ultimi congressi biennali del Peritoneal Surface Oncology Group International (PSOGI), gli eventi in assoluto di maggiore rilevanza scientifica internazionale in questo campo: Parigi, 2018 (www.psogi2018.com), Washington, DC, 2016 (www.psogi.com/meetings/10th-international-congress-on-peritoneal-surface-malignancies-2016), Amsterdam, 2014 (www.psogi.com/meetings/9th-international-congress-on-peritoneal-surface-malignancies), Berlino, 2012 (www.psogi.com/meetings).

Negli ultimi cinque anni, presso la SC di Chirurgia Colo-rettale, ha iniziato e gestito un programma di applicazione delle tecniche di citoriduzione chirurgica complessa (peritonectomia associata a resezioni multiviscerali) all'ambito delle neoplasie colo-rettali avanzate e/o recidive, i cui risultati nei primi 60 casi sono stati recentemente presentati in ambito internazionale al meeting della Society of Surgical Oncology americana (14th International Symposium on Regional Cancer Therapies. Phoenix, AZ. February 16-18, 2019. www.surgonc.org/meetings-events/regional-cancer-therapies).

Recentemente è diventato responsabile clinico e scientifico del progetto di ricerca "*Pilot study of feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.*" (finanziato da Fondo per la Valorizzazione della Ricerca Istituzionale 2018), che ha introdotto per la prima volta all'Istituto Nazionale Tumori la metodica mini-invasiva della PIPAC per il trattamento delle neoplasie del peritoneo.

I più rilevanti contributi scientifici del Dr. Dario Baratti possono essere riassunti come segue:

- Uno studio multi-centrico pilota che costituisce la base razionale per futuri trial randomizzati di trattamento loco-regionale adiuvante in tumori colo-rettali ad alto rischio di metastasi peritoneali. Tale studio ha dimostrato che l'HIPEC eseguita al momento della resezione con intento curativo del primitivo è associata a minore incidenza cumulativa di metastasi peritoneali e migliore sopravvivenza a distanza, a paragone di un gruppo di controllo sottoposto a trattamento standard, senza HIPEC (Baratti D, et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. Ann Surg Oncol. 2017;24:167-175; editoriale dedicato: McAuliffe JC, Nash GM "Adjuvant" Hyperthermic Intraperitoneal Chemotherapy: A Call to Action. Ann Surg Oncol. 2017;24:11-12.)
- Una serie di studi sui fattori prognostici patologici e biologici nel mesotelioma peritoneale. In particolare, lo studio sulle metastasi linfonodali nel mesotelioma è stata la prima pubblicazione a dimostrare il ruolo prognostico dell'interessamento linfonodale in questa neoplasia. Sulla base di questi studi, le metastasi linfonodali e i markers di proliferazione cellulare, quali il Ki-67, sono ora utilizzati routinariamente nei maggiori centri di trattamento delle neoplasie peritoneali per selezionare i pazienti da sottoporre a chirurgia citoriduttiva e HIPEC. (Baratti D, et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45-53. Baratti D, et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140-8.)
- uno studio rivoluzionario che ha cambiato la strategia chirurgica nel mesotelioma peritoneale, sulla base di una migliore conoscenza del comportamento biologico e del pattern di disseminazione peritoneale della malattia. Questo studio ha dimostrato il vantaggio in termini di sopravvivenza di un approccio di peritonectomia parietale totale rispetto al tradizionale approccio di peritonectomia selettiva limitata alle sole aree macroscopicamente interessate dalla malattia (Baratti D, et al. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416-24.)

Esperienze professionali

Periodo	09.2012- data attuale
Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori. Via Venezian, 1 20133 Milano
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Dirigente Medico Struttura Complessa Chirurgia Colo-rettale
Principali mansioni e responsabilità	Esecuzione di interventi chirurgici in pazienti affetti da neoplasie peritoneali primitive e secondarie, e neoplasie colo-rettali avanzate e/o recidive. Coordinazione della gestione clinica pre- e post-operatoria di pazienti affetti da neoplasie peritoneali e neoplasie colo-rettali primitive avanzate e/o recidive. Responsabile dell'ambulatorio istituzionale dedicato ai Tumori Peritoneali (TUPR). Attività di ricerca clinica e traslazionale nell'ambito delle neoplasie peritoneali. Principale investigatore del progetto di ricerca " <i>Pilot study of feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.</i> " (finanziato da Fondo per la Valorizzazione della Ricerca Istituzionale 2018), che ha introdotto per la prima volta all'Istituto Nazionale Tumori la metodica della PIPAC.
Periodo	06.2000 - 08.2012
Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori. Via Venezian, 1 20133 Milano.
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Dirigente Medico Struttura Complessa Chirurgia Melanoma Sarcoma,
Principali mansioni e responsabilità	Esecuzione di interventi chirurgici in pazienti affetti da neoplasie peritoneali primitive e secondarie, e sarcomi dei tessuti molli. Gestione clinica pre- e post-operatoria di pazienti affetti da neoplasie peritoneali e sarcomi dei tessuti molli. Attività ambulatoriale con pazienti affetti da neoplasie peritoneali e sarcomi dei tessuti molli in follow-up o riferiti per prima valutazione all'Istituto Nazionale Tumori. Attività di ricerca clinica e traslazionale nell'ambito delle neoplasie peritoneali.
Periodo	11.1999 - 05.2000
Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori. Via Venezian, 1 20133 Milano.
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Ricercatore associato Unità Operativa Chirurgia Melanoma Sarcoma
Principali mansioni e responsabilità	Esecuzione di interventi chirurgici in pazienti affetti da sarcomi dei tessuti molli degli arti, retro peritoneali, viscerali e GIST. Gestione clinica pre- e post-operatoria di pazienti affetti da neoplasie peritoneali e sarcomi dei tessuti molli. Attività ambulatoriale con pazienti affetti da sarcomi dei tessuti molli in follow-up o riferiti per prima valutazione all'Istituto Nazionale Tumori.

Baratti D. Curriculum vitae | 2019

Attività di ricerca clinica e traslazionale nell’ambito delle neoplasie peritoneali.	
Periodo	01.1998 – 10.1999
Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori. Via Venezian, 1 20133 Milano.
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Ricercatore associato Unità Operativa Chirurgia Apparato Digerente
Principali mansioni e responsabilità	Esecuzione di interventi chirurgici in pazienti affetti da neoplasie del tratto digerente. Gestione clinica di pazienti affetti da neoplasie del tratto digerente. Attività ambulatoriale con pazienti affetti da tratto digerente in follow-up o riferiti per prima valutazione all’Istituto Nazionale Tumori. Attività di ricerca clinica e traslazionale nell’ambito delle neoplasie tratto digerente.
Periodo	01.1994 – 12.1999
Nome e indirizzo del datore di lavoro	Fondazione IRCCS Istituto Nazionale dei Tumori. Via Venezian, 1 20133 Milano.
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Specializzando Divisione Oncologia Chirurgica A (Unità Trapianto di Fegato) Istituto Nazionale dei Tumori, Milano.
Principali mansioni e responsabilità	Attività chirurgica, clinica ed ambulatoriale nell’ambito del trapianto di fegato e della chirurgia resettiva epatica in pazienti affetti da neoplasie epatiche primitive o metastatiche. Membro del team di espianto d’organo per il trapianto epatico. Attività di ricerca clinica e traslazionale nell’ambito delle neoplasie e delle malattie degenerative epatiche.
Periodo	07.1993 – 12.1993
Nome e indirizzo del datore di lavoro	Ospedale Policlinico di Milano - Università degli Studi di Milano. Via F. Sforza, 35 20122 Milano.
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Specializzando II Scuola di Specializzazione in Chirurgia dell’App. Digerente ed Endoscopia Digestiva Chirurgica (II Scuola)
Principali mansioni e responsabilità	Attività chirurgica, clinica ed ambulatoriale nell’ambito della patologia neoplastica dell’apparato digerente, delle malattie infiammatorie intestinali e della chirurgia generale.
Periodo	07.1992 – 06.1993
Nome e indirizzo del datore di lavoro	Comune di Grezzana (VR). Via Roma, 1, 37023 Grezzana VR
Tipo di azienda/settore	Servizi Socio-Sanitari.
Tipo di impiego	Servizio Civile presso Servizi Sociali Comune di Grezzana.
Principali mansioni e responsabilità	Attività socio-sanitaria.

Periodo	10.1988 – 06.1992
Nome e indirizzo del datore di lavoro	Ospedale S. Raffaele di Milano, Cattedra di Patologia Chirurgica - Università degli Studi di Milano. Via Olgettina, 60 20132 Milano
Tipo di azienda/settore	Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Tipo di impiego	Internato Divisione di Chirurgia II
Principali mansioni e responsabilità	Attività chirurgica, clinica ed ambulatoriale nell'ambito della chirurgia generale, con particolare riferimento alle neoplasie colo rettali.

Istruzione e formazione

Data	11.1997
Nome e tipo di istituto di istruzione	Scuola di Specializzazione in Chirurgia dell'Apparato Digerente ed Endoscopia Digestiva Chirurgica (II Scuola) – Università degli Studi di Milano
Principali materie oggetto dello studio	Chirurgia dell'Apparato Digerente ed Endoscopia Digestiva
Qualifica conseguita	Specialista in Chirurgia dell'Apparato Digerente ed Endoscopia Digestiva Chirurgica
Livello nella classificazione nazionale	Votazione 60/60 Tesi sperimentale: "Il trapianto di fegato nel trattamento dell'epatocarcinoma in cirrosi"
Data	23.04.1991
Nome e tipo di istituto di istruzione	Ordine dei Medici della Provincia di Milano
Qualifica conseguita	Abilitazione all'esercizio della professione ed iscrizione all'albo (n. 31006)
Data	07.1990
Nome e tipo di istituto di istruzione	Università degli Studi di Milano
Principali materie oggetto dello studio	Facoltà di Medicina e Chirurgia, Corso di Laurea in Medicina e Chirurgia
Qualifica conseguita	Laurea in Medicina e Chirurgia
Livello nella classificazione nazionale	Votazione 110/110 Tesi sperimentale: "Chirurgia radio-immuno-guidata dei tumori del colon-retto".
Data	06.1983
Nome e tipo di istituto di istruzione	Liceo Classico Giuseppe Parini, Milano
Principali materie oggetto dello studio	Liceo classico
Qualifica conseguita	Maturità Classica

Capacità ed esperienze relazionali

Il Dr. Dario Baratti è Segretario della SITILO (Società Italiana per le Terapie Integrate Loco-regionali in Oncologia), e membro dell’Onco-team della SICO (Società Italiana di Chirurgia Oncologica) dedicato alle neoplasie del peritoneo. In tale gruppo, è promotore e responsabile scientifico del protocollo randomizzato “Studio di fase II randomizzato multicentrico di chemioterapia aerosolizzata intraperitoneale pressurizzata (pressurized intraperitoneal aerosol chemotherapy PIPAC) in pazienti con carcinoma colo-rettale ad alto rischio di sviluppare metastasi peritoneali dopo chirurgia curativa”. Inoltre, è membro del PSOGI (Peritoneal Surface Oncology Group International), della ASPSM (American Association of Peritoneal Surface Malignancies).

Il Dr. Dario Baratti ha tenuto lezioni nell’ambito dei corsi della Scuola di Specializzazione in Chirurgia Generale Dell’Università degli Studi di Milano e, a livello internazionale è stato docente dei seguenti Advanced Courses della European Society of Surgical Oncology (ESSO):

- Management of Peritoneal Surface Malignancies (Bergamo, IT, November 2011)
- Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (Hamburg, GE, March 2015).

Inoltre, è regolarmente coinvolto come revisore da numerose riviste scientifiche internazionali, quali Journal of Surgical Oncology, European Journal of Surgical Oncology, Annals of Surgical Oncology, British Journal of Surgery, Cancer, Annals of Surgery e Journal of Clinical Oncology.

Capacità ed esperienze organizzative

Il Dr Dario Baratti ha strutturato, attraverso la sua formazione formale (Laurea, Scuola di Specializzazione) e professionale presso l’Istituto Nazionale dei Tumori di Milano, una specifica competenza in ambito clinico, metodologico, gestionale ed organizzativo che viene applicata nell’esecuzione, gestione e coordinazione di pazienti, patologie ed attività chirurgiche di elevatissima complessità, quale il trattamento integrato mediante chirurgia citoriduttiva e HIPEC in soggetti affetti da neoplasie del peritoneo. In questo ambito, si segnala una particolare competenza ed esperienza nel coordinare l’attività di equipe all’interno del gruppo chirurgico dedicato alle patologie peritoneali della SC Chirurgia Colo-rettale e nel gestire le collaborazioni con le altre strutture coinvolte a livello clinico e di ricerca traslazionale in queste complesse patologie, in forte integrazione multidisciplinare (Chirurgia Epato-biliare, Oncologia Medica, Anestesia, Terapia Intensiva, Radiologia, Radioterapia, Anatomia Patologica, Laboratorio, Oncologie Sperimentali ed altri servizi).

Dal punto di vista scientifico l’esperienza organizzativa del Dr Dario Baratti comprende numerose collaborazione nell’elaborazione e conduzione di progetti di ricerca finanziati da grant nazionali ed internazionali

- Pilot study of feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.” (Fondo per la Valorizzazione della Ricerca Istituzionale 2018). Investigatore principale
- Pseudomyxoma Peritonei: Optimizing Treatment by Exploring the Connection between Oncogene Mutation and Inflammation (AIRC, 2016). Investigatore collaboratore.
- Effects of Intra-abdominal Pressure on Tissue Diffusion and Pharmacokinetics of Cisplatin during HIPEC (AIRC, 2013). Investigatore collaboratore.
- Pseudomyxoma Peritonei: Prognostic Analysis of Micro-RNA and Other Biological Factors Using Tissue Microarray (National Organization for Rare Disorders, NORD, (USA). MAC 2011 pseudomyxoma peritonei grant award). Investigatore collaboratore.
- Peritoneal Mesothelioma: Optimize Outcomes by the Integration of new Prognostic Factors and Potential Therapeutic Targets in a Individualized Treatment based on Molecular Characterization and Chemosensitivity Profile on Primary Cultures (Ministero della Salute - Ricerca Finalizzata, 2009). Investigatore collaboratore.
- Studio Randomizzato di Fase II per la valutazione di un approccio di revisione chirurgica sistematica, associata a chemio-ipertermia intraperitoneale ed eventuale chirurgia citoriduttiva, versus follow-up standard in pazienti ad alto rischio di sviluppare carcinosi peritoneale da carcinoma colo-rettale. (
- Innovative management of patients with Diffuse Malignant Peritoneal Mesothelioma: Clinical-Diagnostic Pathway and New Therapeutic Targets (Istituto Superiore di Sanità 2007-2011). Investigatore collaboratore.
-

Durante gli ultimi anni ha creato un'importante rete di rapporti di ricerca nazionali e internazionali che ha portato all'esecuzione di numerosi studi clinici oggetto di pubblicazione:

- Chua TC, Moran BJ, Sugabaker PH, Levine EA, Glehen O, Gilly FN, **Baratti D**, et al. Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Clin Oncol.* 2012 Jul 10;30:2449-56.
- Yan TD, Deraco M, **Baratti D**, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugabaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience. *J Clin Oncol.* 2009;20;27:6237-42.
- Kusamura S, Moran BJ, Sugabaker PH, Levine EA, Elias D, **Baratti D**; Peritoneal Surface Oncology Group International (PSOGL). Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. *Br J Surg.* 2014;101:1758-65
- Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, **Baratti D**, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. *Ann Surg Oncol.* 2014;21:4195-201.

Altre competenze personali

Lingua madre

italiano

Lingue straniere

inglese

Comprensione		Parlato		Produzione scritta
Ascolto	Lettura	Interazione	Produzione orale	
B2	B2	B2	B2	C1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Competenze digitali

Elaborazione delle informazioni	Comunicazione	Creazione di contenuti	Sicurezza	Risoluzione di problemi
Utente avanzato	Utente autonomo	Utente autonomo	Utente autonomo	Utente base

Premi e riconoscimenti

- Vincitore del Bando per la Valorizzazione della Ricerca Istituzionale 2018 (BRI) con il progetto "Pilot study of feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer."
- Primo premio al 10° Meeting della Associazione Chirurghi Ospedalieri Italiani (ACOI) per la presentazione "Reverse Spleno-renal Shunt After Liver Transplantation" (Milano, 17.05.1997)
- Autore invitato alla redazione dei capitoli

Baratti D. Peritoneal mesothelioma – Pathology including multicystic peritoneal mesothelioma and well-differentiated papillary peritoneal mesothelioma. Oxford Textbook of Oncology (3rd ed.). Edited by Kerr DJ, Haller DG, van de Velde CJH, Baumann M. Oxford University Press. Oxford, UK, 2016.
DOI:10.1093/med/9780199656103.003.0042_update_001.

Deraco M, **Baratti D**, Kusamura S. Diffuse malignant peritoneal mesothelioma. Cytoreductive surgery and peritonectomy chemotherapy for peritoneal surface malignancy. Textbook and video-atlas. Edited by Sugabaker PH. Cine-Med Publishing Inc. Woodbury, CT, 2013.

Pubblicazioni scientifiche indexate (Pubmed)

Numero totali articoli pubblicati	133
Articoli come primo, ultimo o corresponding author	39 , incluso:
	<ul style="list-style-type: none"> • 5 lettere a Editors (ref. n. 20, 28, 34, 35 66) • 1 co-first authorship (ref. n. 11) • 1 co-last authorship (ref. n. 12)
Numero totale di citazioni	5358
<u>H-index (Scopus)</u>	43

1. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.

Alzahrani NA, Valle SJ, Fisher OM, Sugarbaker PH, Yonemura Y, Glehen O, Goere D, Honore C, Brigand C, de Hingh I, Verwaal VJ, Deraco M, **Baratti D**, Kusamura S, Pocard M, Piso P, Maerz L, Marchal F, Moran B, Levine EA, Dumont F, Pezet D, Abboud K, Kozman MA, Liauw W, Morris DL; Peritoneal Surface Oncology Group International (PSOGI) and Big-RENAPE groups.

J Surg Oncol. 2019 Mar;119(3):336-346. doi: 10.1002/jso.25277. Epub 2018 Dec 16.
PMID: 30554404.

2. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, **Baratti D**, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C.
J Immunol Res. 2018 Oct 29;2018:5804230. doi: 10.1155/2018/5804230. eCollection 2018.
PMID: 30510965.

3. Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

Deraco M, Nizri E, Glehen O, **Baratti D**, Tuech JJ, Bereder JM, Kepenekian V, Kusamura S, Goere D.
Eur J Surg Oncol. 2019 Mar;45(3):371-375. doi: 10.1016/j.ejso.2018.10.065. Epub 2018 Oct 19.
PMID: 30473172.

4. ASO Author Reflections: Pathologic Classification of Pseudomyxoma Peritonei.

Baratti D.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):844-845. doi: 10.1245/s10434-018-6892-9. Epub 2018 Oct 15. No abstract available.
PMID:30324483.

5. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.

Amblard I, Mercier F, Bartlett DL, Ahrendt SA, Lee KW, Zeh HJ, Levine EA, **Baratti D**, Deraco M, Piso P, Morris DL, Rau B, Tentes AAK, Tuech JJ, Quenet F, Akaishi E, Pocard M, Yonemura Y, Lorimier G, Delroeux D, Villeneuve L, Glehen O, Passot G; PSOGI and BIG RENAPE working groups.
Eur J Surg Oncol. 2018 Sep;44(9):1378-1383. doi: 10.1016/j.ejso.2018.04.023. Epub 2018 Jun 19.
PMID: 30131104.

6. Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?

Baratti D, Kusamura S, Iusco D, Cotsogliou C, Guaglio M, Battaglia L, Virzì S, Mazzaferro V, Deraco M.
Dis Colon Rectum. 2018 Sep;61(9):1026-1034. doi: 10.1097/DCR.0000000000001156.
PMID: 30086051.

7. Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC.

Nizri E, Kusamura S, Fallabrino G, Guaglio M, **Baratti D**, Deraco M.

Ann Surg Oncol. 2018 Oct;25(11):3264-3270. doi: 10.1245/s10434-018-6630-3. Epub 2018 Jul 26.
PMID:30051371.

8. Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers.

Kusamura S, González-Moreno S, Nizri E, **Baratti D**, Guadagni S, Guaglio M, Battaglia L, Deraco M.
Surg Oncol Clin N Am. 2018 Jul;27(3):507-517. doi: 10.1016/j.soc.2018.02.009. Review.
PMID: 29935686.

9. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study.

Mehta S, Schwarz L, Spiliotis J, Hsieh MC, Akaishi EH, Goere D, Sugarbaker PH, **Baratti D**, Quenet F, Bartlett DL, Villeneuve L, Kepenekian V; PSOGI and BIG-RENAPE Working Groups.
Eur J Surg Oncol. 2018 Nov;44(11):1786-1792. doi: 10.1016/j.ejso.2018.05.021. Epub 2018 May 28.
PMID: 29885982.

10. Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.

Nizri E, **Baratti D**, Guaglio M, Sinukumar S, Cabras A, Kusamura S, Deraco M.
Eur J Surg Oncol. 2018 Jul;44(7):1100-1104. doi: 10.1016/j.ejso.2018.03.004. Epub 2018 Mar 14.
PMID: 29703622.

11. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.

Bruno F, **Baratti D**, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M.
Eur J Surg Oncol. 2018 Jun;44(6):792-798. doi: 10.1016/j.ejso.2018.02.010. Epub 2018 Feb 17.
PMID: 29503128.

12. Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series.

Guaglio M, Sinukumar S, Kusamura S, Milione M, Pietrantonio F, Battaglia L, Guadagni S, **Baratti D**, Deraco M.
Ann Surg Oncol. 2018 Apr;25(4):878-884. doi: 10.1245/s10434-017-6305-5. Epub 2017 Dec 21. Erratum in: Ann Surg Oncol. 2018 Jan 19;::.
PMID: 29270877.

13. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.

Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, **Baratti D**, Chouliaras K, Russell G, Shen P, Levine EA; RENAPE Working Group.
Ann Surg Oncol. 2018 Mar;25(3):667-673. doi: 10.1245/s10434-017-6293-5. Epub 2017 Dec 19.
PMID: 29260418.

14. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M.
Ann Surg Oncol. 2018 Feb;25(2):404-413. doi: 10.1245/s10434-017-6252-1. Epub 2017 Nov 20.
PMID: 29159742.

15. Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Sardi A, Sipok A, **Baratti D**, Deraco M, Sugarbaker P, Salti G, Yonemura Y, Sammartino P, Glehen O, Bakrin N, Díaz-Montes TP, Gushchin V.
Eur J Surg Oncol. 2017 Nov;43(11):2170-2177. doi: 10.1016/j.ejso.2017.08.011. Epub 2017 Sep 7.
PMID: 28967566.

16. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.

Baratti D, Kusamura S, Milione M, Pietrantonio F, Caporale M, Guaglio M, Deraco M.

Ann Surg Oncol. 2016 Dec;23(13):4222-4230. Epub 2016 Jun 28.
PMID: 27352203.

17. Toward the molecular dissection of peritoneal pseudomyxoma.

Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, Morano F, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, **Baratti D**, Bowne WB, Kusamura S, Deraco M.

Ann Oncol. 2016 Nov;27(11):2097-2103. Epub 2016 Aug 8.
PMID:27502722.

18. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases.

Baratti D, Kusamura S, Iusco D, Gimondi S, Pietrantonio F, Milione M, Guaglio M, Bonomi S, Grassi A, Virzì S, Leo E, Deraco M.

Ann Surg Oncol. 2017 Jan;24(1):167-175. doi: 10.1245/s10434-016-5488-5. Epub 2016 Aug 12.
PMID: 27519353.

19. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, **Baratti D**, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F. J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x.
PMID: 27154293.

20. Comment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A.

Deraco M, Kusamura S, **Baratti D**.
Gynecol Oncol Rep. 2015 Nov 28;15:7-8. doi: 10.1016/j.gore.2015.11.002. eCollection 2016 Jan.
PMID: 26937478.

21. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review.

Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M.
Crit Rev Oncol Hematol. 2016 Apr;100:209-22. doi: 10.1016/j.critrevonc.2016.01.017. Epub 2016 Jan 22. Review.
PMID: 26867984.

22. Treatment principles for peritoneal surface malignancies.

Deraco M, Kusamura S, Corbellini C, Guaglio M, Paviglianiti C, **Baratti D**.
Minerva Chir. 2016 Apr;71(2):124-45. Epub 2016 Feb 5. Review.
PMID: 26847729.

23. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Kusamura S, Torres Mesa PA, Cabras A, **Baratti D**, Deraco M.
Ann Surg Oncol. 2016 May;23(5):1468-73. doi: 10.1245/s10434-015-4962-9. Epub 2015 Nov 16.
PMID: 26572754.

24. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Kusamura S, **Baratti D**, Hutanu I, Gavazzi C, Morelli D, Iusco DR, Grassi A, Bonomi S, Virzì S, Haeusler E, Deraco M.
Eur J Surg Oncol. 2015 Aug;41(8):1097-105. doi: 10.1016/j.ejso.2015.04.005. Epub 2015 May 16.
PMID: 26026742.

25. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.

Deraco M, Cabras A, **Baratti D**, Kusamura S.
Ann Surg Oncol. 2015 Dec;22(13):4344-51. doi: 10.1245/s10434-015-4498-z. Epub 2015 Mar 17.

PMID: 25777091.

26. Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy.

Piccioni F, Casiraghi C, Fumagalli L, Kusamura S, **Baratti D**, Deraco M, Arienti F, Langer M.

Int J Surg. 2015 Apr;16(Pt A):99-106. doi: 10.1016/j.ijsu.2015.02.025. Epub 2015 Mar 11.

PMID: 25771101.

27. Peritoneal metastases: challenges for the surgeon.

Baratti D, Kusamura S, Guaglio M, Deraco M.

Minerva Chir. 2015 Jun;70(3):195-215. Epub 2015 Mar 10. Review.

PMID: 25752673.

28. In reply.

Baratti D, Kusamura S, Maggi C, de Braud F, Deraco M, Di Bartolomeo M, Pietrantonio F.

Oncologist. 2015 Mar;20(3):e5. doi: 10.1634/theoncologist.2014-423.

PMID: 25745055.

29. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma.

Colombo C, **Baratti D**, Kusamura S, Deraco M, Gronchi A.

J Surg Oncol. 2015 Apr;111(5):570-9. doi: 10.1002/jso.23808. Epub 2014 Oct 28. Review.

PMID: 25351775.

30. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei.

Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, **Baratti D**, Morris DL, Sardi A, Glehen O, Deraco M; Peritoneal Surface Oncology Group International (PSOGI).

Br J Surg. 2014 Dec;101(13):1758-65. doi: 10.1002/bjs.9674. Epub 2014 Oct 20.

PMID: 25329419.

31. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.

Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, **Baratti D**, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R.

J Surg Oncol. 2014 Dec;110(7):779-85. doi: 10.1002/jso.23728. Epub 2014 Aug 2.

PMID: 25088304.

32. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M, Perrone F, **Baratti D**, Kusamura S, Tamborini E, Castano A, Consonni PV, Bossi I, Gavazzi C, Milione M, Pelosi G, de Braud F.

Oncologist. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106. Epub 2014 Jun 20.

PMID: 24951608.

33. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.

Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzì S, Leo E, Deraco M.

Dis Colon Rectum. 2014 Jul;57(7):858-68. doi: 10.1097/DCR.0000000000000149.

PMID: 24901687.

34. Colorectal Cancer Peritoneal Metastases: Second-look Laparotomy, Prophylactic HIPEC, or Both?

Baratti D, Kusamura S, Deraco M.

Ann Surg. 2016 Jan;263(1):e5. doi: 10.1097/SLA.0000000000000773.

PMID: 24887973.

35. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer:

Baratti D, Kusamura S, Deraco M.

Lancet Oncol. 2014 Jun;15(7):e249. doi: 10.1016/S1470-2045(14)70197-4.
PMID: 24872106.

36. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.

Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, **Baratti D**, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spilloitis J, Torres-Melero J, Turaga K, Trout R.

Ann Surg Oncol. 2014 Dec;21(13):4195-201. doi: 10.1245/s10434-014-3798-z. Epub 2014 May 23.
PMID: 24854493.

37. Prevention and early treatment of peritoneal metastases from colorectal cancer: second-look laparotomy or prophylactic HIPEC?

Baratti D, Kusamura S, Deraco M.

J Surg Oncol. 2014 Mar;109(3):225-6. doi: 10.1002/jso.23492. Epub 2014 Jan 22.
PMID: 24452990.

38. Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases.

Virzì S, Iusco D, **Baratti D**, Bonomi S, Grassi A, Kusamura S, Deraco M.

Tumori. 2013 Sep-Oct;99(5):589-95. doi: 10.1700/1377.15307.

PMID: 24362862.

39. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutana I, Deraco M.

Eur J Cancer. 2013 Oct;49(15):3140-8. doi: 10.1016/j.ejca.2013.05.027. Epub 2013 Jul 4.

PMID: 23831335.

40. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.

Kusamura S, Hutana I, **Baratti D**, Deraco M.

J Surg Oncol. 2013 Jul;108(1):1-8. doi: 10.1002/jso.23329. Epub 2013 May 29.

PMID: 23720095.

41. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.

Bakrin N, Gilly FN, **Baratti D**, Bereder JM, Quenet F, Lorimier G, Mohamed F, Elias D, Glehen O; Association Française de Chirurgie.

Eur J Surg Oncol. 2013 Jul;39(7):742-7. doi: 10.1016/j.ejso.2013.02.018. Epub 2013 Mar 16.

PMID: 23510853.

42. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Deraco M, **Baratti D**, Hutana I, Bertuli R, Kusamura S.

Ann Surg Oncol. 2013 Apr;20(4):1093-100. doi: 10.1245/s10434-012-2845-x. Epub 2013 Mar 2.

PMID: 23456386

43. The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs.

Kusamura S, **Baratti D**, Hutana I, Rossi P, Deraco M.

Surg Oncol Clin N Am. 2012 Oct;21(4):559-76. doi: 10.1016/j.soc.2012.07.011.

PMID: 23021716.

44. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres.

Kusamura S, **Baratti D**, Virzì S, Bonomi S, Iusco DR, Grassi A, Hutana I, Deraco M.

J Surg Oncol. 2013 Mar;107(4):312-9. doi: 10.1002/jso.23231. Epub 2012 Aug 23.
PMID: 22926536.

45. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Chua TC, Moran BJ, Sugabaker PH, Levine EA, Glehen O, Gilly FN, **Baratti D**, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.

J Clin Oncol. 2012 Jul 10;30(20):2449-56. doi: 10.1200/JCO.2011.39.7166. Epub 2012 May 21.
PMID: 22614976.

46. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy.

Baratti D, Kusamura S, Mingrone E, Balestra MR, Laterza B, Deraco M.
Ann Surg. 2012 Aug;256(2):334-41. doi: 10.1097/SLA.0b013e31825704e3.
PMID: 22580946.

47. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, **Baratti D**, Kusamura S.
BJOG. 2012 Jun;119(7):800-9. doi: 10.1111/j.1471-0528.2011.03207.x.
PMID: 22571746.

48. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.

Baratti D, Kusamura S, Cabras AD, Deraco M.
Ann Surg Oncol. 2012 May;19(5):1416-24. doi: 10.1245/s10434-012-2237-2.
PMID: 22302266.

49. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.

Kusamura S, **Baratti D**, Deraco M.
Ann Surg. 2012 Feb;255(2):348-56. doi: 10.1097/SLA.0b013e3182436c28.
PMID: 22202584.

50. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, **Baratti D**.
Gynecol Oncol. 2011 Aug;122(2):215-20. doi: 10.1016/j.ygyno.2011.05.004. Epub 2011 Jun 12.
PMID: 21665254.

51. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*.

Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugabaker PH, **Baratti D**, Kusamura S, Gilly FN, Shen P, Mohamed F; Peritoneal Surface Oncology Group.
Cancer. 2011 May 1;117(9):1855-63. doi: 10.1002/cncr.25640. Epub 2010 Nov 18.
PMID: 21509762.

52. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research.

Baratti D, Kusamura S, Deraco M.
J Surg Oncol. 2011 Jun;103(8):822-31. doi: 10.1002/jso.21787. Epub 2011 Jan 31. Review.
PMID: 21283990.

53. Experience with peritoneal mesothelioma at the Milan National Cancer Institute.

Deraco M, **Baratti D**, Cabras AD, Zaffaroni N, Perrone F, Villa R, Jocollè J, Balestra MR, Kusamura S, Laterza B, Pilotti S.
World J Gastrointest Oncol. 2010 Feb 15;2(2):76-84. doi: 10.4251/wjgo.v2.i2.76.
PMID: 21160925.

54. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M.

World J Gastrointest Oncol. 2010 Jan 15;2(1):36-43. doi: 10.4251/wjgo.v2.i1.36.

PMID: 21160815.

55. Pathophysiology and biology of peritoneal carcinomatosis.

Kusamura S, **Baratti D**, Zaffaroni N, Villa R, Laterza B, Balestra MR, Deraco M.

World J Gastrointest Oncol. 2010 Jan 15;2(1):12-8. doi: 10.4251/wjgo.v2.i1.12.

PMID: 21160812.

56. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer.

Deraco M, **Baratti D**, Laterza B, Balestra MR, Mingrone E, Macrì A, Virzì S, Puccio F, Ravenda PS, Kusamura S.

Eur J Surg Oncol. 2011 Jan;37(1):4-9. doi: 10.1016/j.ejso.2010.11.004. Epub 2010 Nov 26. Review.

PMID: 21112721.

57. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.

Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugabaker PH; Chua TC, Yan TD, Morris DL, Deraco M, **Baratti D**, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Sugabaker PH, Moran BJ, Mohamed F, Glockzin G, Piso P; Peritoneal Surface Oncology Group.

Br J Surg. 2011 Jan;98(1):60-4. doi: 10.1002/bjs.7263. Epub 2010 Sep 24.

PMID: 20872843.

58. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M.

Eur J Surg Oncol. 2010 Nov;36(11):1047-53. doi: 10.1016/j.ejso.2010.08.130. Epub 2010 Sep 15.

PMID: 20832234.

59. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.

Perrone F, Jocollè G, Pennati M, Deraco M, **Baratti D**, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S.

Eur J Cancer. 2010 Oct;46(15):2837-48. doi: 10.1016/j.ejca.2010.06.130. Epub 2010 Aug 6.

PMID: 20692828.

60. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M.

Ann Surg Oncol. 2010 Dec;17(12):3220-8. doi: 10.1245/s10434-010-1178-x. Epub 2010 Jun 29. Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S327. Alessanrdro, Gronchi [corrected to Gronchi, Alessandro].

PMID: 20585874.

62. Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Scivales A, Balestra MR, Ponzi P, Di Stasi F, Kusamura S, Laterza B, Deraco M.

Eur J Surg Oncol. 2010 May;36(5):463-9. doi: 10.1016/j.ejso.2010.03.005. Epub 2010 Apr 2.

PMID: 20363094.

63. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

Yan TD, Deraco M, **Baratti D**, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugabaker PH.

J Clin Oncol. 2009 Dec 20;27(36):6237-42. doi: 10.1200/JCO.2009.23.9640. Epub 2009 Nov 16.

PMID: 19917862.

64. Lymph node metastases in diffuse malignant peritoneal mesothelioma.
Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco MAnn Surg Oncol. 2010 Jan;17(1):45-53. doi: 10.1245/s10434-009-0756-2. Epub 2009 Oct 24.
PMID: 19856030.
65. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies.
Deraco M, **Baratti D**, Kusamura S, Laterza B, Balestra MR.
J Surg Oncol. 2009 Sep 15;100(4):321-8. doi: 10.1002/jso.21388. Review.
PMID: 19697439.
66. Circulating CA125 and diffuse malignant peritoneal mesothelioma.
Baratti D, Kusamura S, Deraco M.
Eur J Surg Oncol. 2009 Nov;35(11):1198-9. doi: 10.1016/j.ejso.2009.04.007. Epub 2009 May 6.
PMID: 19423265.
67. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma.
Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M.
In Vivo. 2009 Jan-Feb;23(1):187-90.
PMID: 19368148.
68. Colobronchial fistula: an unusual complication after peritonectomy and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Laterza B, Baratti D, Cozzi G, Kusamura S, Oliva GD, Gavazzi C, Fumagalli L, Sironi A, Sabia D, Deraco M.
In Vivo. 2009 Jan-Feb;23(1):151-3.
PMID: 19368141.
69. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M.
Ann Surg. 2009 Feb;249(2):243-9. doi: 10.1097/SLA.0b013e31818eec64.
PMID: 19212177
70. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.
Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.
PMID: 19082859.
71. The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy.
Kusamura S, **Baratti D**, Younan R, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):217-9. doi: 10.1002/jso.21059. Review.
PMID: 18726907.
72. The consensus statement on the locoregional treatment of abdominal sarcomatosis.
Rossi CR, Casali P, Kusamura S, **Baratti D**, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):291-4. doi: 10.1002/jso.21067. Review.
PMID: 18726899.
73. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.
Helm CW, Bristow RE, Kusamura S, **Baratti D**, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):283-90. doi: 10.1002/jso.21083. Review.
PMID: 18726895.
74. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei).

Moran B, **Baratti D**, Yan TD, Kusamura S, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):277-82. doi: 10.1002/jso.21054. Review.
PMID: 18726894.

75. Locoregional treatment of peritoneal carcinomatosis from gastric cancer.
Bozzetti F, Yu W, **Baratti D**, Kusamura S, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):273-6. doi: 10.1002/jso.21052. Review.
PMID: 18726891.

76. Consensus statement on peritoneal mesothelioma.
Deraco M, Bartlett D, Kusamura S, **Baratti D**.
J Surg Oncol. 2008 Sep 15;98(4):268-72. doi: 10.1002/jso.21055. Review.
PMID: 18726890.

77. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination.
Esquivel J, Elias D, **Baratti D**, Kusamura S, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):263-7. doi: 10.1002/jso.21053. Review.
PMID: 18726889.

78. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus.
Baratti D, Kusamura S, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):258-62. doi: 10.1002/jso.21056.
PMID: 18726888.

79. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy.
Younan R, Kusamura S, **Baratti D**, Cloutier AS, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):253-7. doi: 10.1002/jso.21057. Review.
PMID: 18726887.

80. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
Kusamura S, Dominique E, **Baratti D**, Younan R, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):247-52. doi: 10.1002/jso.21051. Review.
PMID: 18726886.

81. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion.
Glehen O, Cotte E, Kusamura S, Deraco M, **Baratti D**, Passot G, Beaujard AC, Noel GF.
J Surg Oncol. 2008 Sep 15;98(4):242-6. doi: 10.1002/jso.21061. Review.
PMID: 18726885.

82. Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy.
González-Moreno S, Kusamura S, **Baratti D**, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):237-41. doi: 10.1002/jso.21072. Review.
PMID: 18726884.

83. Technical aspects of cytoreductive surgery.
Kusamura S, O'Dwyer ST, **Baratti D**, Younan R, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):232-6. doi: 10.1002/jso.21058. Review.
PMID: 18726883.

84. The eligibility for local-regional treatment of peritoneal surface malignancy.
Verwaal VJ, Kusamura S, **Baratti D**, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):220-3. doi: 10.1002/jso.21060. Review.
PMID: 18726879.

85. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.

Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, **Baratti D**, Deraco M, Costa A, Reddel RR, Zaffaroni N.

Clin Cancer Res. 2008 Jul 1;14(13):4134-40. doi: 10.1158/1078-0432.CCR-08-0099.

PMID: 18593991.

86. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M.

In Vivo. 2008 Jan-Feb;22(1):153-7.

PMID: 18396799.

87. [Updated treatment of peritoneal carcinomas: a review].

Deraco M, Laterza B, Kusamura S, **Baratti D**.

Minerva Chir. 2007 Dec;62(6):459-76. Review. Italian.

PMID: 18091656.

88. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M.

Ann Surg Oncol. 2008 Feb;15(2):526-34. Epub 2007 Nov 28.

PMID: 18043976.

89. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma.

Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, **Baratti D**, Deraco M, Daidone MG.

Cell Oncol. 2007;29(6):453-66.

PMID: 18032822.

90. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Kusamura S, **Baratti D**, Antonucci A, Younan R, Laterza B, Oliva GD, Gavazzi C, Deraco M.

Ann Surg Oncol. 2007 Dec;14(12):3443-52. Epub 2007 Oct 2.

PMID: 17909918.

91. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution.

Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A.

Ann Surg Oncol. 2007 Dec;14(12):3542-51. Epub 2007 Oct 2.

PMID: 17909905.

92. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Oct;14(10):2790-7. Epub 2007 Jul 28.

PMID: 17661150.

93. Morbidity and quality of life following cytoreduction and HIPEC.

Deraco M, **Baratti D**, Kusamura S.

Cancer Treat Res. 2007;134:403-18. Review.

PMID: 17633069.

94. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.

Kusamura S, **Baratti D**, Younan R, Laterza B, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Grossi F, Deraco M.

Ann Surg Oncol. 2007 Sep;14(9):2550-8. Epub 2007 Jun 9.

PMID: 17558537.

95. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M.

Ann Surg Oncol. 2007 Aug;14(8):2300-8. Epub 2007 May 18.

PMID: 17510772.

96. Advances in clinical research and management of diffuse peritoneal mesothelioma.

Deraco M, **Baratti D**, Zaffaroni N, Cabras AD, Kusamura S.

Recent Results Cancer Res. 2007;169:137-55.

PMID: 17506257.

97. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.

Deraco M, Kusamura S, Laterza B, Favaro M, Fumagalli L, Costanzo P, **Baratti D**.

In Vivo. 2006 Nov-Dec;20(6A):773-6.

PMID: 17203766.

98. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Feb;14(2):500-8. Epub 2006 Dec 6.

PMID: 17151789.

99. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.

Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, **Baratti D**, Bartlett D, Barone R, Barrios P, Bielik S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G; Society of Surgical Oncology Annual Meeting.

Ann Surg Oncol. 2007 Jan;14(1):128-33. Epub 2006 Oct 28. Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S334-5.
PMID: 17072675.

100. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.

Nonaka D, Kusamura S, **Baratti D**, Casali P, Younan R, Deraco M.

Histopathology. 2006 Oct;49(4):381-7.

PMID: 16978201.

101. Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique.

Kusamura S, Deraco M, **Baratti D**, Inglese MG, Costanzo P, Favaro M, Manzi R, Gavazzi C.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):207-12.

PMID: 16767933.

102. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.

Raspagliosi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, **Baratti D**, Mariani L, Laterza B, Deraco M.

Eur J Surg Oncol. 2006 Aug;32(6):671-5. Epub 2006 Apr 18.

PMID: 16621425.

103. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.

Kusamura S, Younan R, **Baratti D**, Costanzo P, Favaro M, Gavazzi C, Deraco M.

Cancer. 2006 Mar 1;106(5):1144-53.
PMID: 16456817.

104. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

Deraco M, Nonaka D, **Baratti D**, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S. Ann Surg Oncol. 2006 Feb;13(2):229-37. Epub 2006 Jan 18.
PMID: 16444562.

105. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.

Nonaka D, Kusamura S, **Baratti D**, Casali P, Cabras AD, Younan R, Rosai J, Deraco M. Cancer. 2005 Nov 15;104(10):2181-8.
PMID: 16206294.

106. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion.

Younan R, Kusamura S, **Baratti D**, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M. Ann Surg Oncol. 2005 Nov;12(11):910-8. Epub 2005 Sep 21.
PMID: 16177862.

107. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study.

Kusamura S, Raspagliesi F, **Baratti D**, Gronchi A, Casali P, Deraco M. J Chemother. 2004 Nov;16 Suppl 5:19-22.
PMID: 15675470.

108. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei.

Deraco M, **Baratti D**, Inglese MG, Allaria B, Andreola S, Gavazzi C, Kusamura S. Ann Surg Oncol. 2004 Apr;11(4):393-8.
PMID: 15070599.

109. [Peritoneal mesothelioma: results of a complicated and aggressive procedure incorporating peritonectomy and intraperitoneal hyperthermic chemotherapy, and prospects derived from bench-to-bedside research].

Deraco M, Kusamura S, **Baratti D**, Casali P, Zaffaroni N. Tumori. 2003 Jul-Aug;89(4 Suppl):56-7. Italian.
PMID: 12903546.

110. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.

Deraco M, Casali P, Inglese MG, **Baratti D**, Pennacchioli E, Bertulli R, Kusamura S. J Surg Oncol. 2003 Jul;83(3):147-53.
PMID: 12827682.

111. Chordoma: natural history and results in 28 patients treated at a single institution.

Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Ann Surg Oncol. 2003 Apr;10(3):291-6.
PMID: 12679315.

112. Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients.

Luzi L, Regalia E, Pulvirenti A, Piceni Sereni L, Spessot M, Romito R, **Baratti D**, Terruzzi I, Mazzaferro V. Acta Diabetol. 2002 Dec;39(4):203-8.
PMID: 12486494.

113. Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response.

Bozzetti F, Andreola S, **Baratti D**, Mariani L, Stani SC, Valvo F, Spinelli P. Ann Surg Oncol. 2002 Jun;9(5):444-9.

PMID: 12052754.

114. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.
Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, **Baratti D**, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, Casali PG. Cancer. 2001 Sep 1;92(5):1259-64.

PMID: 11571741

115. [Principles of oncologic radicality in the surgical treatment of gastric carcinoma].
Bozzetti F, Bignami P, **Baratti D**, Mancino G. Ann Ital Chir. 2001 Jan-Feb;72(1):19-26. Review. Italian.
PMID: 11464490.

116. Surgical strategies in colorectal cancer metastatic to the liver.
Bozzetti F, Bignami P, **Baratti D**. Tumori. 2000 Jan-Feb;86(1):1-7.
PMID: 10778758.

117. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.
Perseghin G, Mazzaferro V, Sereni LP, Regalia E, Benedini S, Bazzigaluppi E, Pulvirenti A, Leão AA, Calori G, Romito R, **Baratti D**, Luzi L. Hepatology. 2000 Mar;31(3):694-703.
PMID: 10706560

118. Preoperative radiation therapy for patients with T2-T3 carcinoma of the middle-to-lower rectum.
Bozzetti F, **Baratti D**, Andreola S, Zucali R, Schiavo M, Spinelli P, Gronchi A, Bertario L, Mariani L, Gennari L. Cancer. 1999 Aug 1;86(3):398-404.
PMID: 10430246.

119. Effect of liver transplantation in cirrhotic diabetic patients.
Perseghin G, **Baratti D**, Benedini S, Regalia E, Mazzaferro V, Luzi L. Transplant Proc. 1998 Aug;30(5):1868. No abstract available.
PMID: 9723314.

120. Impact of distal clearance margin on oncologic outcome after restorative resection of the rectum.
Bozzetti F, Mariani L, Miceli R, Montalto F, **Baratti D**, Andreola S. Tumori. 1997 Nov-Dec;83(6):907-11.
PMID: 9526582.

121. Surgical treatment of locally recurrent rectal carcinoma.
Bozzetti F, Bertario L, Rossetti C, Gennari L, Andreola S, **Baratti D**, Gronchi A. Dis Colon Rectum. 1997 Dec;40(12):1421-4.
PMID: 9407978.

122. Regulation of glucose homeostasis in humans with denervated livers.
Perseghin G, Regalia E, Battezzati A, Vergani S, Pulvirenti A, Terruzzi I, **Baratti D**, Bozzetti F, Mazzaferro V, Luzi L. J Clin Invest. 1997 Aug 15;100(4):931-41.
PMID: 9259593.

123. Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma.
Mazzaferro V, Brunetto MR, Pasquali M, Regalia E, Pulvirenti A, **Baratti D**, Makowka L, Van Thiel D, Bonino F. J Viral Hepat. 1997 Jul;4(4):235-42.
PMID: 9278221.

124. Metabolic effects of liver transplantation in cirrhotic patients.

Luzi L, Perseghin G, Regalia E, Sereni LP, Battezzati A, **Baratti D**, Bianchi E, Terruzzi I, Hilden H, Groop LC, Pulvirenti A, Taskinen MR, Gennari L, Mazzaferro V.
J Clin Invest. 1997 Feb 15;99(4):692-700.
PMID: 9045872

125. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.
Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, **Baratti D**, Romano F, Palazzo U, Zuin M, Bonino F, Ribero ML, Gennari L.
Transplant Proc. 1997 Feb-Mar;29(1-2):519-21.
PMID: 9123113.

126. Renal-splenic shunt for infrahepatic caval occlusion after piggy-back liver transplantation.
Mazzaferro V, Regalia E, Pulvirenti A, **Baratti D**, Montagnino G, Bozzetti F.
Transpl Int. 1997;10(5):392-4.
PMID: 9287406.

127. Preoperative radiotherapy for resectable cancer of the middle-distal rectum: its effect on the primary lesion as determined by endorectal ultrasound using flexible echo colonoscope.
Bozzetti F, Andreola S, Rossetti C, Zucali R, Meroni E, **Baratti D**, Bertario L, Doci R, Gennari L.
Int J Colorectal Dis. 1996;11(6):283-6.
PMID: 9007624.

128. Successful liver transplantation from a donor with chromosomal abnormality (45,XO).
Pulvirenti A, Regalia E, Bianchi E, Zuin M, Gennari L, **Baratti D**, Mazzaferro V.
Transplant Proc. 1994 Dec;26(6):3655-6. No abstract available.
PMID: 7998309.

129. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin.
Paganelli G, Stella M, Zito F, Magnani P, De Nardi P, Mangili F, **Baratti D**, Veglia F, Di Carlo V, Siccardi AG, et al.
J Nucl Med. 1994 Dec;35(12):1970-5.
PMID: 7989979.

130. Avidin-biotin system in radioimmunoguided surgery for colorectal cancer. Advantages and limits.
Stella M, De Nardi P, Paganelli G, Magnani P, Mangili F, Sassi I, **Baratti D**, Gini P, Zito F, Cristallo M, et al.
Dis Colon Rectum. 1994 Apr;37(4):335-43.
PMID: 8168412.

131. Surgery for colorectal cancer guided by radiodetecting probe. Clinical evaluation using monoclonal antibody B72.3.
Stella M, De Nardi P, Paganelli G, Sassi I, Zito M, Magnani P, **Baratti D**, Mangili F, Spagnolo W, Siccardi AG, et al.
Eur J Surg. 1991 Aug;157(8):485-8.
PMID: 1681938.

132. [The role of B72.3 125-I monoclonal antibody in the radioimmunoguided surgery of colorectal neoplasms].
Di Carlo V, Stella M, De Nardi P, **Baratti D**, Sassi I, Mangili F, Zito M, Badellino F, Dionigi R, Fazio F.
Ann Ital Chir. 1991 May-Jun;62(3):245-9. Italian.
PMID: 1755605.

133. [The new prospects for radioimmunoguided surgery: the avidin-biotin system].
Stella M, De Nardi P, Paganelli G, Sassi I, Magnani P, **Baratti D**, Mangili F, Spagnolo W, Fazio F,
Di Carlo V.
Ann Ital Chir. 1991 May-Jun;62(3):231-4. Italian.
PMID: 1755602.

Partecipazioni a congressi internazionali come relatore e/o moderatore

Colorectal peritoneal metastases treated by systemic chemotherapy and cytoreductive surgery with or without HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). 14th International Symposium on Regional Cancer Therapies. Phoenix, AZ. February 16-18, 2019.

Prognostic impact of primary side and RAS/RAF mutations on surgically resected peritoneal metastases from colorectal cancer. 11th Peritoneal Surface Oncology Group International (PSOGI) World Congress on Peritoneal Surface Malignancies. Paris, France. September 9-11, 2018.

RAS/RAF mutations in surgically resected peritoneal metastases from colorectal cancer. 13th International Symposium on Regional Cancer Therapies. Jacksonville, FLA. February 17-19, 2018.

Prophylactic HIPEC in the treatment of locally advanced colorectal cancer. 12th International Colo-Rectal cancer Club (ICRCC) Congress on Colorectal Cancer. Saint-Petersburg, Russia. September 8-9 2017.

Comprehensive treatment of peritoneal surface malignancies. 6th Congress of Oncologists and Radiologist of Kazakhstan. Almaty, Kazakhstan. April 27-28, 2017.

Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single Center Series of 244 Patients Treated by CRS/HIPEC 12th International Symposium on Regional Cancer Therapies. Snowbird, UT, February 18-20. 2017.

Chair of the Meet the Professor Breakfast. Starting a new peritoneal surface oncology program 10th Peritoneal Surface Oncology Group International (PSOGI) World Congress on Peritoneal Surface Malignancies. Washington, DC. October 31-November 2nd 2016.

Colon cancer peritoneal carcinomatosis: clinical evidences. Adjuvant HIPEC in locally advanced colorectal cancer. 2° International Conference on Surgical Oncology. Perugia, IT. October 23-25, 2016

Peritoneal surface malignancies treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): colo-rectal cancer. 34th Annual Conference of the International Clinical Hyperthermia Society. Pesaro, IT. September 22, 2016

Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases Combined with Curative Surgery for Hematogenous Metastases: Analysis of Early and Long-Term Outcomes. 11th International Symposium on Regional Cancer Therapies. Chandler, AZ, February 13-15. 2016.

Clinical diagnostic pathway for peritoneal surface malignancies. European Society of Surgical Oncology (ESSO) Advanced Course: Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery. Hamburg, GE, March 19-21, 2015

Malignant Peritoneal Mesothelioma: Incorporation of a Novel Pathologic Grading into a Recently Proposed tnM Classification Improves Outcome Prediction 10th International Symposium on Regional Cancer Therapies. Clearwater Beach, FLA. February 14-16. 2015.

Matched Case-Control Study of HIPEC for the Prevention and Early Treatment of Colorectal Cancer Peritoneal Metastases. 9th Peritoneal Surface Oncology Group International (PSOGI) World Congress on Peritoneal Surface Malignancies. Amsterdam The Netherlands. October 9-11 2014.

Extra-appendiceal Origin does not Affect Prognosis in Patients with Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and HIPEC 9th International Symposium on Regional Cancer Therapies. Steam Boat Springs, NV. February 15-17. 2014.

Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer. 8th International Symposium on Regional Cancer Therapies. Indian Wells, CA. February 16-18. 2014.

Diffuse malignant peritoneal mesothelioma: 7-year actual survival after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) defines cure. 7th International Symposium on Regional Cancer Therapies. Captiva Island, FLA. February 18-20. 2013.

Baratti D. Curriculum vitae | 2019

Disease management: sarcoma and other rare diseases. (Expert panel) 8th Peritoneal Surface Oncology Group International (PSOGI) World Congress on Peritoneal Surface Malignancies. Berlin, Germany. October 31-November 2nd 2012.

Diffuse malignant peritoneal mesothelioma: 7-year actual survival after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy defines cure. 11th International Conference of the International Mesothelioma Interest Group (IMIG) September 12-14, 2012

Diffuse malignant peritoneal mesothelioma: 7-year actual survival after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) defines cure. 7th International Symposium on Regional Cancer Therapies. Captiva Island, FLA. February 18-20. 2012.

Preoperative evaluation and patient selection: circulating tumor markers. European Society of Surgical Oncology (ESSO) Advanced Course: Management of Peritoneal Surface Malignancies. Bergamo, IT, November 27-29, 2011.

Complete versus selective peritonectomy does not increase the risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. 6th International Symposium on Regional Cancer Therapies. Incline Village, FLA. February 19-21. 2011.

Is there a subset of patients with peritoneal sarcomatosis who may benefit of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy? 62th Annual Cancer Symposium of the Society of Surgical Oncology. Saint Louis, MS. March 4-7, 2010.

Is there a subset of patients with peritoneal sarcomatosis who may benefit of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy? Fifth International Symposium on Regional Cancer Therapies. San Juan, Puerto Rico. February 18-20, 2010

Diffuse malignant peritoneal mesothelioma: clinical. Pathological and biological prognostic analysis in a series of 99 patients treated by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). 7th International Workshop on Peritoneal Surface Malignancy. Uppsala, Sweden. September 8-10, 2010.

Lymph-node Metastases in patients with Diffuse Malignant Peritoneal Mesothelioma. 62th Annual Cancer Symposium of the Society of Surgical Oncology. Phoenix, AZ. March 4-8, 2009.

Prognostic Significance of Lymph-Node Metastases in Patients with Diffuse Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and HIPEC. 4th International Symposium on Regional Cancer Therapies. Marco Island, FLA. February 21-23. 2009.

Diffuse Malignant Peritoneal Mesothelioma: Prognostic Significance of Lymph-node Metastases. 6th International Workshop on Peritoneal Surface Malignancy. Lyon, France. November 17-19, 2008.

Biological features are the dominant prognostic determinants for patients affected by pseudomyxoma peritonei undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy 6th International Workshop on Peritoneal Surface Malignancy. Lyon, France. November 17-19, 2008.

Diffuse Malignant Peritoneal Mesothelioma: Analysis of Treatment Failure Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. 61th Annual Cancer Symposium of the Society of Surgical Oncology. Chicago, IL. March 13-16, 2008.

Pseudomyxoma peritonei: biological features are the dominant prognostic determinants following complete cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). 3rd International Symposium on Regional Cancer Therapies. Desert Spring, CA. February 16-18, 2008.

Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). 60th Annual Cancer Symposium of the Society of Surgical Oncology. Washington, DC. March 15-18, 2007.

Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma (DMPM). 2nd International Symposium on Regional Cancer Therapies. San Juan, Puerto Rico. February 24-26, 2007.

Expanding the Indications of Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy. 2nd International Symposium on Regional Cancer Therapies. San Juan, Puerto Rico. February 24-26, 2007.

Introduction to disease consensus. 5th International Workshop on Peritoneal Surface Malignancy. Milan, Italy. December 4-6, 2006

Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC). 59th Annual Cancer Symposium of the Society of Surgical Oncology. San Diego, CA. March 23-26, 2006.

Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. 59th Annual Cancer Symposium of the Society of Surgical Oncology. San Diego, CA. March 23-26, 2006.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.



Milano, 15 marzo 2019

Dario Baratti